R. Haupt, M. Minkov, and I. Astigarraga, Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatr Blood Cancer, vol.60, pp.213-232, 2010.

J. Donadieu, F. Bernard, and M. Van-noesel, Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study, Blood, vol.126, pp.1415-1423, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01231424

H. Gadner, N. Grois, and U. Pötschger, Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008.

R. Haupt, V. Nanduri, and M. G. Calevo, Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group, Pediatr Blood Cancer, vol.42, pp.438-444, 2004.

, Cell Histiocytosis Study Group: A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group, Arch Dis Child, vol.75, pp.17-24, 1996.

M. Berres, K. Lim, and T. Peters, Recurrent BRAF mutations in Langerhans cell histiocytosis, vol.211, pp.1919-1923, 2010.

T. Satoh, A. Smith, and A. Sarde, B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease, PLoS One, vol.7, issue.e33891, 2012.

J. Haroche, C. F. Arnaud, and L. , High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses, Blood, vol.120, pp.2700-2703, 2012.

J. Haroche, F. Cohen-aubart, and E. , Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, vol.121, pp.836-838, 2000.

, Pediatr Blood Cancer, vol.51, pp.71-75, 2008.

C. Rigaud, M. Barkaoui, and C. Thomas, Langerhans cell histiocytosis: Therapeutic strategy
URL : https://hal.archives-ouvertes.fr/hal-01331987

J. Donadieu, C. Piguet, and F. Bernard, Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Expert Opin Pharmacother, vol.43, pp.1309-1322, 2004.

S. Moreau, P. Saiag, and P. Aegerter,

, Ann Surg Oncol, vol.19, pp.4314-4321, 2012.

D. Pekin, Y. Skhiri, and J. Baret, Congenital solitary histiocytoma: A variant of Hashimoto-Pritzker histiocytosis. A retrospective study of 8 cases, Dermatology, vol.11, pp.118-124, 2008.

J. Henter, A. Horne, and M. Aricó, Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease, HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, vol.48, pp.64-71, 2015.

M. Kobayashi and A. Tojo, The BRAF-V600E mu, vol.124, pp.2610-2611, 2014.

M. Affiliations-sébastien-héritier, J. Barkaoui, J. Miron, and . Donadieu, French Reference Center for Langerhans Cell Histiocytosis

S. Héritier, S. Boudjemaa, G. Leverger, and J. Donadieu, Trousseau Hospital

S. Fraitag, D. Moshous, and C. Bodemer,

M. Peuchmaur and B. Lescoeur, Robert Debré Hospital

M. Peuchmaur,

H. Pacquement, Institut Curie Medical Center

G. Leverger, U. Pierre, and M. Curie,

F. Cohen, -. , and J. Haroche, Pitié-Salpêtrière Hospital

R. Lacave, Tenon Hospital

S. Héritier, J. Emile, Z. Hélias-rodzewicz, and J. Donadieu,

J. Emile, Ambroise Paré Hospital

C. Thomas and A. Moreau, Nantes

A. Lambilliotte and F. Mazingue,

F. Dijoud and H. Femme-mère-enfant,

K. Kebaili, Institut d'Hémato-Oncologie Pediatrique, Lyon; Valérie Rigau, Gui de Chauliac Hospital

E. Jeziorski, M. Arnaud-de-villeneuve, and . Plat, Claire Galambrun

C. Paillard,

A. Deville,

C. Armari-alla,

A. Lutun, Centre Hospitalo-Universitaire d

M. Gillibertyvert,

I. Pellier,

V. Gandemer,

A. Ferster, Memorial Sloan Kettering Cancer Center